Leaders in Medicine and Science Celebrate Innovation at the Feinstein Institutes During Two Annual Academic Events
'The Feinstein Institutes' commitment to translational research was evident throughout this two-day celebration,' said Bettie M. Steinberg, PhD, interim dean of the Elmezzi Graduate School of Molecular Medicine and professor in the Feinstein Institutes Institute of Molecular Medicine. 'The symposium highlighted cutting-edge discoveries poised to move from the lab to the clinic, while the Elmezzi graduates represent the next generation of scientists dedicated to turning scientific advancements into tangible therapies.'
Meeting of minds at the Feinstein Academy of Scholars Symposium
Members of the Academy include recipients of honorary doctoral degrees from the Elmezzi Graduate School of Molecular Medicine, Marsh and Match visiting lecturers, recipients of the Cerami, Ross and Advancing Women in Science and Medicine (AWSM) prizes, and researchers from the Feinstein Institutes.
This year's featured keynote speakers included:
Tobias Janowitz, MD, PhD, associate professor and Cancer Center Program Leader at Cold Spring Harbor Laboratory, provided an overview of the current research on systemic signaling in paraneoplasia, emphasizing the importance of this area of study.
Lopa Mishra, MD, co-director and professor in the Institute of Bioelectronic Medicine at the Feinstein Institutes and Susan and Herman Merinoff Distinguished Chair in Translational Medicine, explained how specific environmental toxins contribute to liver cancer and outlined methods to selectively target these cancer cells.
Akiko Iwasaki, PhD, Sterling Professor of Immunology at Yale University School of Medicine, spoke about examining the role of immune dysregulation in the pathogenesis of post-acute infection syndrome.
Douglas F. Nixon, MD, PhD, Karches Family Professor in Translational Research and director and professor, Institute of Translational Research at the Feinstein Institutes, spoke about human endogenous retroviruses (HERVs) are part of our non-coding DNA and that our own genomes can impact our health and disease.
Max Brenner, MD, PhD, associate professor in the Institute of Molecular Medicine at the Feinstein Institutes, spoke about an Elmezzi scholar's scientific journey stemming from the classroom to the clinic and the lab.
Linda Van Aelst, PhD, professor at Cold Spring Harbor Laboratory, discussed the intricate involvement of Rho regulators in synapse formation and dysfunction.
Celebrating the future of medical research
On May 22, two clinicians were conferred their PhD during the Elmezzi Graduate School of Molecular Medicine graduation. This unique PhD program is for physicians (MDs) who wish to pursue careers in biomedical research. During the program, Elmezzi students conduct research in Feinstein Institutes laboratories to advance medical research and pursue new therapeutic approaches and diagnostic tools. The Elmezzi Graduate School of Molecular Medicine is supported in part by a generous endowment from the Thomas and Jeanne Elmezzi Foundation.
Two honorary degrees were bestowed at the Elmezzi commencement. The first to Dr. Iwasaki for her research on immune defense against viruses at mucosal surfaces, and to Dr. Rothblatt for her contributions to new treatments for rare diseases and advances in organ transplants. In addition, she was the creator of the satellite radio company SiriusXM. This year's graduates include:
Willians Tambo Ayol, MD, investigated the role of microvascular dysfunction in cognitive impairment and dementia, and explored the therapeutic potential of the diving reflex's protective mechanisms against cerebral hypoperfusion.
Santhoshi Poonacha Palandira, MBBS, MS, MCh, applied optogenetics to neuromodulate brainstem nuclei to regulate inflammation. She also identified celiac-superior mesenteric ganglion complex in the abdomen and identified it as a new therapeutic target for noninvasive bioelectronic therapies to treat inflammation with a translational potential.
'Physician-scientists produce the innovations and discoveries that make a healthier world,' said Kevin J. Tracey, MD, president and CEO of Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. 'Elmezzi graduates are committed to career paths that will lead to new therapies and diagnostics.'
To find out more about the Elmezzi Graduate School of Molecular Medicine and its programs, click here.
About The Elmezzi Graduate School of Molecular Medicine:
The Elmezzi Graduate School of Molecular Medicine at Northwell Health offers MDs an accelerated PhD three-year program emphasizing translational research. Its mission is to provide academic training for physicians to discover and understand the causes of human diseases and to rapidly and effectively translate this information into diagnostic and therapeutic solutions. The program started in 1994 and is supported in part by a generous endowment from The Thomas and Jeanne Elmezzi Foundation. To date, more than 50 physician-scientists have graduated from the prestigious program. The Elmezzi School of Molecular Medicine is accredited by the WASC Senior College and University Commission (WSCUC). For more information, click here.
About the Feinstein Institutes
The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research. We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 days ago
- Business Wire
United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended June 30, 2025, driven by continued double-digit year-over-year revenue growth in key products such as Tyvaso DPI, Nebulized Tyvaso, Orenitram, and Unituxin. Total revenues in the second quarter of 2025 grew 12 percent year-over-year to a record $798.6 million, compared to $714.9 million in the second quarter of 2024. 'Our second quarter yet again produced record-setting results driven by the strength of our foundational commercial business,' said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. 'We continue to believe there is no other biotech company like ours that provides this combination of sales growth and operating cash flow with near- to medium-term catalysts positioned for sustained long-term growth, starting with data from the TETON 2 study of nebulized treprostinil in idiopathic pulmonary fibrosis expected in September that could fundamentally improve options for patients with this progressive, deadly disease with few treatments available. 'Equally, our strong financial position, confidence in these upcoming catalysts, and belief in our share price potential has led our Board of Directors to authorize up to $1 billion in share repurchases, affirming our commitment to a robust and balanced capital allocation philosophy.' Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, added, 'We're proud of the continued record performance for Tyvaso DPI, a best-in-class treprostinil dry powder inhaler that allows the flexibility of one breath per cartridge, four times a day, with low inspiratory effort. Further, no other commercially available treprostinil dry powder inhaler has been clinically studied with published data at higher doses 1,2 or prescribed by more physicians to more patients than Tyvaso DPI. 'We expect continued double digit revenue growth for Tyvaso and total revenues well into the future through strong commercial execution of our existing product portfolio coupled with the potential for our late-stage pipeline in pulmonary fibrosis and pulmonary hypertension.' Second Quarter 2025 Financial Results Key financial highlights include (dollars in millions, except per share data): Revenues The table below presents the components of total revenues (dollars in millions): (1) Net product sales include both the drug product and the respective inhalation device. (2) Net product sales include sales of infusion devices, including the Remunity ® Pump. Expand Total Tyvaso revenues grew by 18 percent to $469.6 million in the second quarter of 2025, compared to $398.2 million in the second quarter of 2024. The growth in Tyvaso DPI revenues resulted primarily from an increase in quantities sold of $54.6 million and, to a lesser extent, a price increase, partially offset by higher gross-to-net revenue deductions. The increase in Tyvaso DPI quantities sold was primarily due to continued growth in the number of patients following the product's launch, including growth in utilization by patients with pulmonary hypertension associated with interstitial lung disease and, to a lesser extent, increased commercial utilization following the implementation of the Medicare Part D benefit redesign under the Inflation Reduction Act (IRA). The growth in Nebulized Tyvaso revenues resulted primarily from an increase in quantities sold and, to a lesser extent, a price increase. The growth in Orenitram revenues resulted primarily from an increase in quantities sold of $10.6 million and, to a lesser extent, a price increase, partially offset by higher gross-to-net revenue deductions. The increase in quantities sold was driven, at least in part, by increased commercial utilization following the implementation of the Medicare Part D benefit redesign under the IRA. The table below presents the breakdown of total revenues between the United States and rest-of-world (ROW) (in millions): (1) Net product sales include both the drug product and the respective inhalation device. (2) Net product sales include sales of infusion devices, including the Remunity Pump. Expand Expenses Cost of sales. The table below summarizes cost of sales by major category (dollars in millions): (1) See Share-based compensation below. Expand Cost of sales, excluding share-based compensation. Cost of sales for the three months ended June 30, 2025 increased as compared to the same period in 2024, primarily due to an increase in: (1) royalty expense resulting from a growth in revenues; and (2) reserve expense resulting from increased production. Research and development. The table below summarizes the nature of research and development expense by major expense category (dollars in millions): (1) External research and development primarily includes fees paid to third parties (such as clinical trial sites, contract research organizations, and contract laboratories) for preclinical and clinical studies and payments to third-party contract manufacturers before FDA approval of the relevant product. (2) Internal research and development primarily includes salary-related expenses for research and development functions, internal costs to manufacture product candidates before FDA approval, and internal facilities-related expenses, including depreciation, related to research and development activities. (3) See Share-based compensation below. (4) Other primarily includes upfront fees and milestone payments to third parties under license agreements related to development-stage products and adjustments to the fair value of our contingent consideration obligations. Expand Research and development, excluding share-based compensation. Research and development expense for the three months ended June 30, 2025 decreased as compared to the same period in 2024, primarily due to $36.0 million in upfront non-refundable license payments for drug delivery device technologies in 2024, partially offset by: (1) increased expenditures in 2025 related to manufactured organ and organ alternative projects; and (2) a $5.0 million milestone payment made in 2025 for drug delivery device technologies. Selling, general, and administrative. The table below summarizes selling, general, and administrative expense by major category (dollars in millions): (1) Excluding impairment of PP&E. See Impairment of PP&E section below. (2) Calculation is not meaningful. (3) See Share-based compensation below. Expand General and administrative, excluding impairment of PP&E and share-based compensation. General and administrative expense for the three months ended June 30, 2025 increased as compared to the same period in 2024, primarily due to: (1) personnel expense due to growth in headcount; and (2) legal expenses related to litigation matters. Impairment of PP&E. During the three months ended June 30, 2025, we recorded a $21.7 million impairment charge to write down the carrying value of certain PP&E. Share-based compensation. The table below summarizes share-based compensation expense by major category (dollars in millions): The decrease in share-based compensation expense for the three months ended June 30, 2025, as compared to the same period in 2024, was primarily due to a decrease in STAP expense, as all remaining STAP awards were exercised during the first quarter of 2025. Income tax expense. Income tax expense for the three months ended June 30, 2025 and 2024 was $98.9 million and $77.2 million, respectively. Our effective income tax rate (ETR) for the three months ended June 30, 2025 and 2024 was 24 percent and 22 percent, respectively. Our ETR for the three months ended June 30, 2025 increased compared to our ETR for the three months ended June 30, 2024, primarily due to a decrease in excess tax benefits from share-based compensation. Webcast We will host a webcast to discuss our second quarter 2025 financial results on Wednesday, July 30, 2025, at 9:00 a.m. Eastern Time. The webcast can be accessed live via our website at An investor presentation is available now, and after the webcast a replay of the webcast will also be available, at the same location on our website. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun; we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs. You can learn more about what it means to be a PBC here: Forward-Looking Statements Statements included in this press release that are not historical in nature are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements related to our share repurchase program, the anticipated timing and outcome of the TETON 2 and TETON 1 clinical trials of Nebulized Tyvaso in idiopathic pulmonary fibrosis, including potential for these studies to improve options for patients with this disease; the anticipated readout of the ADVANCE OUTCOMES clinical trial of ralinepag; our near- to medium-term catalysts positioned for sustained long-term growth; our expectation of continued double digit revenue growth for Tyvaso and total revenues well into the future through strong commercial execution of our existing product portfolio coupled with the potential for our late-stage pipeline in pulmonary fibrosis and pulmonary hypertension; and our goals of innovating for the unmet medical needs of our patients and to benefit our other stakeholders, furthering our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of July 30, 2025, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason. ORENITRAM, REMODULIN, REMUNITY, TYVASO, TYVASO DPI, and UNITUXIN are registered trademarks of United Therapeutics Corporation and/or its subsidiaries. ADCIRCA is a registered trademark of Eli Lilly and Company. SELECTED CONSOLIDATED BALANCE SHEET DATA (Unaudited, in millions) June 30, 2 025 Cash, cash equivalents, and marketable investments $ 4,966.4 Total assets 7,908.0 Total liabilities 734.4 Total stockholders' equity 7,173.6 Expand Category: Earnings
Business Wire
17-07-2025
- Business Wire
Feinstein Institutes Researchers Find COVID-19 Vaccine Boosters Offer Significant Protection for Cancer Patients
BUSINESS WIRE)--Approximately 81 percent of the U.S. population received at least one dose of the COVID-19 vaccine, and now, researchers from Northwell Health's Feinstein Institutes for Medical Research found that COVID-19 vaccine booster shots provide important protection against severe COVID-19 illness with hospitalization for people living with cancer. The retrospective cohort study, published today in JAMA Oncology, observed over 70,000 patients across four U.S. health systems — including Northwell — and examined the effectiveness of both the monovalent (original) and bivalent (updated) COVID-19 boosters. They found that both boosters significantly reduced COVID-19 hospitalizations. 'COVID-19 vaccines can offer another layer of protection for individuals navigating cancer treatment,' said James M. Crawford, MD, PhD, professor in the Institute of Health System Sciences at the Feinstein Institutes and co-PI of the study. 'This research provides critical information for doctors and patients making decisions about COVID-19 vaccination, especially for vulnerable groups.' The study showed that the both the monovalent and bivalent boosters reduced hospitalizations for whom by nearly 30 percent. While these boosters were effective, the study also revealed a concerning trend: booster uptake among cancer patients was lower than expected, with 69 percent receiving the monovalent booster and only 38 percent receiving the bivalent booster. 'Dr. Crawford and his team's research provides vital knowledge that could help protect the health and well-being of immunocompromised people, like those living with cancer,' said Ping Wang, MD, professor and chief scientific officer and senior vice president at the Feinstein Institutes. 'This study highlights the value of vaccination, particularly for those most vulnerable to serious illnesses.' The study also compared the effectiveness of the boosters in cancer patients to their effectiveness in people without compromised immune systems. While the percentage reduction in hospitalizations was similar between the two groups, the number of people who needed to be vaccinated to prevent a single hospitalization was much smaller for cancer patients. About the Feinstein Institutes The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research. We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program. For more information about how we produce knowledge to cure disease, visit and follow us on LinkedIn.
Forbes
16-07-2025
- Forbes
How The First Atom Bomb Created A New Kind Of Minerals
The mushroom cloud of the Trinity test in New Mexico. On July 16, 1945, the first atomic bomb exploded at the White Sands test site in the desert of New Mexico. The nuclear fission of 6.1 kilograms of plutonium resulted in a blast equivalent to over 20,000 tons of TNT. Even if the bomb was detonated at the top of a 30-meter tall steel tower, the explosion created a crater over 2 meters deep and 40 meters wide. The ground was covered with a glass-like material as never seen before. Clarence S. Ross of the U.S. Geological Survey writes in a contemporary report that "the glass, in general, formed a layer 1 to 2 centimeters thick, with the upper surface marked by a very thin sprinkling of dust which fell upon it while it was still molten. At the bottom is a thicker film of partly fused material, which grades into the soil from which it was derived. The color of the glass is a pale bottle green, and the material is extremely vesicular, with the size of the bubbles ranging to nearly the full thickness of the specimen." Typical pieces of Trinitite, a new mineral created by the blast of the first atomic bomb and named ... More after the test site. The first atomic device was a fission bomb with a plutonium core and uranium shell. About 9 kilograms of U-235 underwent fission, contributing to the overall energy release. A variety of different radioactive isotopes and elements were created in the resulting nuclear reactions. The desert sand at the test site is composed mostly of grains of quartz and feldspar, with small crystals of calcite, hornblende, and augite mixed in. The initial radiation burst was over 8,000 degrees Celsius hot, instantly vaporizing the steel tower and much of the superficial layers, mixing the elements from the minerals with the radioactive elements and traces of iron, forming a new and unique chemical mix.. Droplets of melt rained down from the rising nuclear plume, quickly cooling they formed a glassy layer extending to a radius of 300 meters all around the explosion site. This new radioactive mineral was later named trinitite after the project's codename 'Trinity.' White Sands, New Mexico. Aerial view of the aftermath of the Trinity test, 28 hours after the ... More explosion. The smaller crater to the southeast is from the earlier detonation of 100 tons of TNT. The dark area is covered by trinitite from the nuclear blast Just a few weeks later, on August 6, 1945, the first atomic bomb used in warfare detonated approximately 580 meters above Hiroshima — a city of 350,000 located on the coastal plain of the Chugoku region in western Honshu, Japan. The enormous blast instantly destroyed most of the city and claimed around 70,000 lives. 'Man unleashed the atom to destroy man, and another chapter in human history opened," wrote the New York Times the next day. The Hiroshima bombing not only changed human history, but like the Trinity test created a new kind of mineral that may even enter the geological record. In 2015, geologist Mario Wannier visited the shores near Hiroshima to collect some sand samples. Searching for microfossils, he discovered small particles of melted metal, glass beads and fragments of a rubber-like substance in the samples collected on Miyajima Island and Motoujina Peninsula. Together with researchers at the Lawrence Berkeley National Laboratory, Wannier studied the mineralogical composition of the particles, discovering that they likely formed when the atomic blast vaporized parts of Hiroshima. The researchers named them hiroshimaites. Optical microscopy image with a collection of metallic spherules and cemented fragments fused ... More together by the blast of the atomic bomb dropped over Hiroshima. Unlike naturally occurring glass, like tektites or obsidian, the minerals created by an atomic blast show an unique chemical composition, with elements like silicon, carbon, aluminum and iron (derived from human-made materials like steel, concrete and rubber) mixed together with radioactive elements. Such minerals may be found at other former nuclear test sites around the world, ranging from the deserts of the United States to the remote tundra of Siberia, from the Australian outback to the atolls of the Pacific, and the mountains of North Korea, India, and Pakistan. They are likely stable enough to endure for millions of years — a signature in the rocks, marking humanity's ingenuity in manipulating the very fabric of matter, and perhaps our folly in ever creating such a weapon.
